| scholarly article | Q13442814 |
| P50 | author | Christine M. Lovly | Q82683894 |
| Vered Stearns | Q87723624 | ||
| Gregory P. Kalemkerian | Q124968136 | ||
| Razelle Kurzrock | Q56614941 | ||
| P2093 | author name string | Donald A Berry | |
| Maria E Arcila | |||
| Alan P Venook | |||
| Robert J Morgan | |||
| Al B Benson | |||
| Toni K Choueiri | |||
| Mary W Redman | |||
| Robert W Carlson | |||
| Amy E McKee | |||
| Joan McClure | |||
| Anthony J Olszanski | |||
| David Ross Camidge | |||
| Valerie Guild | |||
| Marian L Birkeland | |||
| P2860 | cites work | Adaptive clinical trials: the promise and the caution | Q82966805 |
| Why do phase III clinical trials in oncology fail so often? | Q83852472 | ||
| Adaptive trials receive boost | Q84098515 | ||
| Molecular wanderings through the DNA damage response and risk for ovarian cancer | Q86821628 | ||
| Master Protocol for squamous cell lung cancer readies for launch | Q87257788 | ||
| I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer | Q87402519 | ||
| Trial offers new model for drug development | Q87403593 | ||
| Neratinib Graduates to I-SPY 3 | Q88009562 | ||
| Reactivity of a monoclonal antibody with human ovarian carcinoma | Q24600879 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| A binding domain on mesothelin for CA125/MUC16 | Q24658397 | ||
| Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond | Q27026323 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance | Q27824818 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. | Q54124954 | ||
| Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? | Q54382589 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| Trial watch: phase II and phase III attrition rates 2011-2012. | Q55057294 | ||
| Prognostic value of KIT expression in small cell lung cancer | Q80125019 | ||
| HER2 status and benefit from adjuvant trastuzumab in breast cancer | Q80959592 | ||
| Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition | Q27852827 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies | Q30458424 | ||
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 | ||
| Clinical analysis and interpretation of cancer genome data | Q30617093 | ||
| Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. | Q30664326 | ||
| Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer | Q33390775 | ||
| Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens | Q33559365 | ||
| The biology of ovarian cancer: new opportunities for translation | Q33622369 | ||
| Resistance to Raf inhibition in cancer | Q33651779 | ||
| Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. | Q33827057 | ||
| Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer | Q34013850 | ||
| Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer | Q34174466 | ||
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs | Q34175045 | ||
| Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma | Q34222257 | ||
| CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease | Q34334247 | ||
| ALK in lung cancer: past, present, and future | Q34402260 | ||
| Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. | Q34473636 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value | Q34755943 | ||
| Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping | Q34760933 | ||
| Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial | Q35119211 | ||
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Q35680026 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer | Q35982635 | ||
| NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy | Q36318627 | ||
| A framework for identification of actionable cancer genome dependencies in small cell lung cancer | Q36342432 | ||
| Translating genomic information into clinical medicine: lung cancer as a paradigm | Q36354845 | ||
| Bayesian clinical trials | Q36399554 | ||
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer | Q36422709 | ||
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | Q36568988 | ||
| Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy | Q36718954 | ||
| Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication | Q37075412 | ||
| Current approaches for neoadjuvant chemotherapy in breast cancer | Q37135365 | ||
| Tissue biomarkers in renal cell carcinoma: issues and solutions | Q37259415 | ||
| Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer | Q37603346 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis | Q37895891 | ||
| Adaptive clinical trials in oncology | Q37953783 | ||
| Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer | Q38001552 | ||
| Clinical treatment decisions for advanced renal cell cancer | Q38109141 | ||
| Molecular profiling and the reclassification of cancer: divide and conquer | Q38110027 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Information technology and precision medicine | Q38209185 | ||
| National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 | ||
| Acquired resistance to TKIs in solid tumours: learning from lung cancer | Q38224967 | ||
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer | Q38322114 | ||
| Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis | Q38453932 | ||
| Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung | Q40142424 | ||
| EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population | Q42206365 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. | Q42739081 | ||
| Risk assessment in Stage II colorectal cancer. | Q43131834 | ||
| Kit expression in small cell carcinomas of the lung: effects of chemotherapy | Q44618346 | ||
| KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors | Q45151889 | ||
| Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial | Q46221067 | ||
| Herceptin: increasing survival in metastatic breast cancer | Q46385256 | ||
| Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial | Q46424154 | ||
| A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. | Q46640878 | ||
| Next generation clinical trials | Q48428021 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. | Q52846071 | ||
| Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. | Q53178811 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. | Q53465653 | ||
| P433 | issue | 11 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1629-1649 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Journal of the National Comprehensive Cancer Network | Q400309 |
| P1476 | title | NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies | |
| P478 | volume | 12 |
| Q37729980 | A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come |
| Q36294743 | A decision support framework for genomically informed investigational cancer therapy |
| Q35810461 | Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA |
| Q89206835 | Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples |
| Q37269473 | Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer |
Search more.